The global drug-coated balloons market size to cross USD 1.5 billion by 2025, growing at a CAGR of 15% during the forecast period. The global drug-coated balloons market is one of the fastest-growing segments in the cardiovascular devices market. The market is growing significantly due to the surge in incidence/prevalence of cardiovascular diseases, especially peripheral artery and coronary artery diseases across the globe.
Cardiovascular diseases are characterized by coronary artery disease (CAD) and peripheral artery disease (PAD). PAD is the third leading cause of atherosclerotic vascular morbidity, which affects approximately 200 million people worldwide. Besides, about 3.8 million men and 3.4 million women die from CAD per year. DCB technology is highly innovative and expected to influence the existing treatment modalities of vascular diseases and ESRD to a great extent. The introduction of DCBs has been a significant breakthrough in the cardiovascular industry with great high potential in terms of minimizing restenosis.
The COVID-19 pandemic is likely to profoundly affect the drug-coated balloons market in several countries across the globe. With the spread of the pandemic, several hospitals, CATH labs, and ASCs have experienced a rapid decline in the volume of elective cardiology procedures. Although COVID-19 is a global pandemic, some countries have experienced a higher incidence of the virus than others.
- The increasing preference for percutaneous procedures with DCBs due to promising outcomes is one of the key driving factors for the global market.
- North America will witness the highest growth rate over the forecast period, with over 16% globally.
- The increasing focus on clinical trial outcomes is a significant factor for the global drug-coated balloons market.
- The ASCs end-user segment is projected to grow at the highest CAGR of over 16% during the forecast period.
GLOBAL DRUG-COATED BALLOONS MARKET SEGMENTATION
This research report includes a detailed segmentation by
- Drug Type
INSIGHTS BY INDICATION
The peripheral artery disease (PAD) segment accounted for a share of over 81% in 2019, and it is expected to retain its market dominance during the forecast period. The adoption of drug-coated balloons (DCB) for treating PAD is growing rapidly, primarily due to the availability of positive clinical data, supporting the safety and efficacy of DCB technology. The segment accounts for the largest share as the majority of DCB devices are commercially available for PAD indication. However, despite high potential growth opportunities for treating PAD, the recent COVID-19 pandemic has caused unprecedented challenges to perform PCI procedures. The spread of the virus has triggered disruption across the globe with lockdowns, travel bans, and ban on large gatherings such as major cardiac scientific society meetings being canceled, with substantial pressure on the health care services across the world.
In 2019, the coronary artery disease (CAD) segment constituted over 11% of the global drug-coated balloons market. The market is growing at a significant rate and is likely to grow during the forecast period. The growth in the CAD patient pool globally is a major key factor for the growth of the segment. Cardiovascular diseases, especially CAD, are recognized as the leading cause of death globally. Moreover, a high prevalence of CAD in developing countries such as India, a significant health challenge, is likely to influence the segment growth.
INSIGHTS BY DRUG TYPE
The paclitaxel segment accounts for the maximum market share as these devices are safe and effective in treating CVDs, AV, and urological disorders. Paclitaxel-coated balloon (PCB) technology has emerged as a promising therapeutic alternative in the PCI procedure, especially for CVDs. The majority of commercially available DCBs are paclitaxel-coated. Paclitaxel-coated balloons are clinically proven, reducing the risk of restenosis after angioplasty of atherosclerotic femoropopliteal lesions. This is increasing their demand among healthcare professionals. In 2019, the sirolimus segment accounted for over 3% of the market. This segment is a new generation of DCBs, where balloons are coated with a medicine called sirolimus. There are a few commercially available sirolimus DCBs. Thus the contribution of the segment is low than paclitaxel-coated balloons.
INSIGHTS BY END-USER
The global drug-coated balloons market is segmented into hospitals, freestanding CATH labs, and ASCs. Healthcare professionals in hospitals use DCBs mainly for cardiovascular disorders, including AV interventions, urological, and neurovascular procedures. The segment is growing at a healthy rate due to the high adoption of the latest generation DCBs. A majority of patients with an increased risk of cardiovascular diseases prefer visiting hospitals for treatment due to advanced infrastructure facilities available in major private and public hospitals, the segment is expected to grow significantly.
In 2019, the freestanding CATH labs' end-user segment accounted for over 28% share. Freestanding CATH labs offer several advantages for patients that need endovascular procedures and significant financial benefits to health care professionals. Europe and France have the highest number of freestanding CATH labs, with around 2.9 freestanding CATH labs per one million. The presence of favorable reimbursement procedures is an essential factor contributing to the segment growth. These labs use cutting edge technology to perform several heart procedures. Continued technological innovations are helping freestanding CATH labs to perform minimally invasive procedures, which is increasing their market revenue.
INSIGHTS BY GEOGRAPHY
North America occupies a dominant position in the global drug-coated balloons market. The presence of a large disease population, coupled with better access to treatment, is the primary factor for the high market share. The market in North America is expected to witness lucrative growth during the forecast period due to expanded indication approvals for commercialized DCBs, new product approvals, and the availability of abundant clinical evidence.
The outcome from several clinical trials conducted in North America, especially in the US, is promising and encouraging physicians to use DCBs for treating various arterial diseases. The adoption of DCBs is likely to increase due to the future availability of positive clinical data, supporting the safety and efficacy of DCB technology in the region. The rise in the number of CVD, ESRD patient pool, and the necessity to treat the disease with endovascular procedures boost the market growth during the forecast period.
INSIGHTS BY VENDORS
The global drug-coated balloons market is highly dynamic with the presence of global, regional, and local players offering a broad range of latest-generation DCBs for end-users. Medtronic, BD, Koninklijke Philips, Boston Scientific, and B. Braun Melsungen are the key vendors in the market in terms of technology, safety features, regulatory approvals, marketing strategies, and distribution channels.
These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovation, strategic mergers & acquisitions, and research activities. Vendors, especially global players, are increasingly focusing on pursuing inorganic growth strategies such as acquisitions and investments in startup and emerging companies to expand their presence, enhance product portfolio, and improve expertise in the industry.
The drug-coated balloons market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
Segmentation by Indication
By Drug Type
- Ambulatory Care Settings
- Freestanding Cath Labs
- North America
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa